Helsinn Healthcare
Helsinn Healthcare, a Swiss-based pharmaceutical company, has established itself as a leader in the oncology and supportive care sectors since its founding in 1977. Headquartered in Lugano, Switzerland, Helsinn operates globally, with significant presence in Europe, North America, and Asia. The company is renowned for its innovative approach to developing high-quality products that enhance the quality of life for cancer patients, including its flagship anti-emetic treatments. With a strong commitment to research and development, Helsinn has achieved notable milestones, including strategic partnerships and a robust pipeline of therapies. Its dedication to patient-centric solutions and a focus on unmet medical needs have positioned Helsinn as a trusted name in the healthcare industry, recognised for its contributions to cancer care and supportive therapies.
DitchCarbon Score
How does Helsinn Healthcare's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Helsinn Healthcare's score of 18 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Helsinn Healthcare's reported carbon emissions
In 2023, Helsinn Healthcare reported an emissions intensity of approximately 17,700 kg CO2e per employee, reflecting their ongoing commitment to sustainability. This figure indicates a slight increase from 2022, where the emissions intensity was about 16,300 kg CO2e per employee. In 2021, Helsinn's total carbon emissions were approximately 3,370,000 kg CO2e, with Scope 1 emissions at about 1,175,000 kg CO2e, Scope 2 emissions at around 340,000 kg CO2e, and Scope 3 emissions reaching approximately 1,855,000 kg CO2e. This data highlights the company's significant carbon footprint, particularly in Scope 3, which includes emissions from business travel and employee commuting. Despite the lack of specific reduction targets or initiatives disclosed, Helsinn Healthcare's emissions data suggests a focus on monitoring and reporting their carbon impact. The company has not yet established Science-Based Targets Initiative (SBTi) reduction targets or formal climate pledges, indicating an area for potential growth in their climate commitments. Overall, Helsinn Healthcare's emissions data reflects their current environmental impact and underscores the importance of setting clear reduction goals to enhance their sustainability efforts in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2021 | |
|---|---|---|---|---|---|---|
| Scope 1 | 2,955,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | - | 0,000,000 | 0,000,000 | 000,000 |
| Scope 3 | - | - | - | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Helsinn Healthcare is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
